Suppr超能文献

β-内酰胺类抗生素的复兴。

β-Lactam Antibiotics Renaissance.

机构信息

ISOF-CNR Department of Chemistry "G. Ciamician", Via Selmi, 2 I-40126 Bologna, Italy.

Allecra Therapeutics SAS, 13, rue de Village-Neuf, F-68300 St-Louis, France.

出版信息

Antibiotics (Basel). 2014 May 9;3(2):193-215. doi: 10.3390/antibiotics3020193.

Abstract

Since the 1940s β-lactam antibiotics have been used to treat bacterial infections. However, emergence and dissemination of β-lactam resistance has reached the point where many marketed β-lactams no longer are clinically effective. The increasing prevalence of multidrug-resistant bacteria and the progressive withdrawal of pharmaceutical companies from antibiotic research have evoked a strong reaction from health authorities, who have implemented initiatives to encourage the discovery of new antibacterials. Despite this gloomy scenario, several novel β-lactam antibiotics and β-lactamase inhibitors have recently progressed into clinical trials, and many more such compounds are being investigated. Here we seek to provide highlights of recent developments relating to the discovery of novel β-lactam antibiotics and β-lactamase inhibitors.

摘要

自 20 世纪 40 年代以来,β-内酰胺类抗生素一直被用于治疗细菌感染。然而,β-内酰胺类抗生素耐药性的出现和传播已经达到了许多市售β-内酰胺类抗生素不再具有临床疗效的程度。多药耐药菌的日益流行以及制药公司逐步退出抗生素研究引发了卫生当局的强烈反应,他们已采取措施鼓励发现新的抗菌药物。尽管前景黯淡,但最近已有几种新型β-内酰胺类抗生素和β-内酰胺酶抑制剂进入临床试验阶段,还有更多此类化合物正在研究中。在此,我们旨在提供与新型β-内酰胺类抗生素和β-内酰胺酶抑制剂的发现相关的最新进展要点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00d8/4790388/99ab41e133b0/antibiotics-03-00193-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验